177Lu-PSMA Radioligand Therapy for Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer: A Case Report and Literature Review
-
Abstract
Objective: To investigate the efficacy and safety of ¹⁷⁷Lu-PSMA radioligand therapy (RLT) in an elderly, heavily pretreated patient with metastatic castration-resistant prostate cancer (mCRPC).
Methods: An 84-year-old man was diagnosed with prostate adenocarcinoma (Gleason score 5 + 4 = 9) with multiple bone metastases in 2015, and had previously undergone bilateral orchiectomy, treatment with ≥6 hormonal agents, two lines of chemotherapy, and olaparib combined with abiraterone. Prior to RLT, his prostate-specific antigen (PSA) level was 841.9 μg/L, and ⁶⁸Ga-PSMA-11 PET/CT (as applicable) demonstrated intense PSMA expression (SUVmax 89.28). He received four cycles of ¹⁷⁷Lu-PSMA therapy beginning in April 2026.
Results: After treatment, PSA decreased to 333 μg/L, representing an approximately 60.4% decline from baseline and meeting the PSA50 response criterion. Neuron-specific enolase (NSE) returned to normal, and PSMA PET/CT showed shrinkage of the primary tumor and a slight reduction in the extent of bone metastases. Toxicity was limited to grade 1 symptoms, including dizziness, fatigue, dry mouth, nausea, urinary urgency, and frequency; no serious adverse events occurred. Complete blood counts showed mild declines (grade 1), and overall tolerability was acceptable.
Conclusion: This case suggests that PSMA PET/CT serves as the basis for patient selection, and that advanced age is not an absolute contraindication to ¹⁷⁷Lu-PSMA RLT. Comprehensive assessment of performance status, bone marrow reserve, and hepatic and renal function, together with monitoring throughout treatment, is warranted. However, given the limited follow-up of this single case, the durability of the response requires validation in larger cohorts.
-
-